Prognostic factors in Hodgkin lymphoma

References

• Josting A, Wolf J, Diehl V. Hodgkin`s disease. Prognostic factors and treatment strategies. Curr. Opin. Oncol.12, 403–411 (2000).
   PubMed Web of Science ®Google Scholar
• Küppers R. The biology of Hodgkin´s Lymphoma. Nat. Rev. Cancer9, 15–27 (2009).
   PubMed Web of Science ®Google Scholar
• Küppers R, Yahalom J, Josting A. Advances in biology, diagnostics and treatment of Hodgkin’s disease. Biol. Blood Marrow Transplant.12(1 Suppl. 1), 66–76 (2006).
   PubMed Web of Science ®Google Scholar
• Klimm B, Reineke T, Haverkamp H et al. Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. J. Clin. Oncol.23(31), 8003–8011 (2005).
   PubMed Web of Science ®Google Scholar
• Behringer K, Josting A, Schiller P et al. Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann. Oncol.15(7), 1079–1085 (2004).
   PubMed Web of Science ®Google Scholar
• Rüffer JU, Flechtner H, Tralls P et al. Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur. J. Cancer15, 2179–2186 (2003).
   Google Scholar
• Rueffer U, Josting A, Franklin J et al. Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group (GHSG) – incidence, treatment and prognosis. J. Clin. Oncol.19(7), 2026–2032 (2001).
   PubMed Web of Science ®Google Scholar
• Josting A, Wiedenmann S, May M et al. Incidence, treatment and prognosis of secondary leukemia and secondary myelodysplastic syndrome in patients treated for Hodgkin’s disease in the German Hodgkin Study Group (GHSG). Blood98(11), 1414 (2001).
   Google Scholar
• Josting A. Relapsed and refractory Hodgkin’s disease. Turkish J. Hematol.24(1 Suppl. 1), 31–36 (2007).
   Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin´s disease. N. Engl. J. Med.339, 1506–1514 (1998).
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood107, 52–59 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstone A. The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin’s disease in first remission. Ann. Oncol.9(Suppl. 5), S83–S85 (1998).
   Google Scholar
• Mauch P, Tarbell N, Weinstein H et al. Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J. Clin. Oncol.6, 1576–1583 (1988).
   PubMed Web of Science ®Google Scholar
• Loeffler M, Pfreundschuh M, Hasenclever D et al. Prognostic risk factors in advanced Hodgkin’s disease. Report of the German Hodgkin Study Group. Blut56, 273–281 (1988).
   PubMedGoogle Scholar
• Carde P, Burger JM, Henry-Amar M et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J. Clin. Oncol.6, 239 (1988).
   PubMed Web of Science ®Google Scholar
• Loeffler M, Pfreundschuh M, Rühl U et al. Risk factor adapted treatment of Hodgkin’s lymphoma: strategies and perspectives. Recent Results Cancer Res.117, 142–162 (1989).
   PubMedGoogle Scholar
• Lagarde P, Eghbali H, Bonichon F et al. Brief chemotherapy associated with extended field radiotherapy in Hodgkin’s disease. Long-term results in a series of 102 patients with clinical stages I–IIIA. Eur. J. Cancer Clin. Oncol.24(7), 1191–1198 (1988).
   PubMedGoogle Scholar
• Specht LK, Hasenclever D. Prognostic factors of Hodgkin’s disease. In: Hodgkin’s Disease. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (Eds). Lippincott Williams and Wilkins, PA, USA 295 (1999).
   Google Scholar
• Gisselbrecht C, Mounier N, André M et al. How to define intermediate stage in Hodgkin’s lymphoma? Eur. J. Haematol.7(Suppl. 66), 11–14 (2005).
   Google Scholar
• Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J. Clin. Oncol.14(5), 1421–1430 (1996).
   PubMed Web of Science ®Google Scholar
• Proctor S, Taylor P, Mackie M et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk. Lymphoma7(Suppl.), 17–20 (1992).
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Schmitz N, Diehl V. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin’s disease? German Hodgkin’s Lymphoma Study Group (GHSG). Leuk. Lymphoma15(Suppl. 1), 47–49 (1995).
   PubMed Web of Science ®Google Scholar
• Fisher R, De VV, Hubbard S et al. Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann. Intern. Med.90, 761–765 (1979).
   PubMed Web of Science ®Google Scholar
• Longo D, Duffey P, Young R et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol.10, 210–218 (1992).
   PubMed Web of Science ®Google Scholar
• Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP/ABVD. J. Clin. Oncol.15, 528–534 (1997).
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J et al. Procnostic factors and treatment outcome in primary progressive Hodgkin`s lymphoma – a report from the German Hodgkin`s Lymphoma Study Group (GHSG). Blood96(4), 1280–1286 (2000).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet359(9323), 2065–2071 (2002).
   PubMed Web of Science ®Google Scholar
• Lohri A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience to 1970–1988. Blood77(10), 2292–2298 (1991).
   PubMed Web of Science ®Google Scholar
• Fermè C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann. Oncol.6(6), 543–549 (1995).
   PubMed Web of Science ®Google Scholar
• Reece D, Barnett M, Shepherd J et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16–213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood86, 451–458 (1995).
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Divine M et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer78(6), 1293–1299 (1996).
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M et al. A new prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J. Clin. Oncol.20(1), 221–230 (2002).
   PubMed Web of Science ®Google Scholar
• Nogová L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma hematology. Am. Soc. Hematol. Educ. Program266–272 (2006).
   PubMedGoogle Scholar
• Steidl C, Lee, T, Shah, SP et al. Tumor-associated macrophages and survival in classic Hodgkin´s Lymphoma. N. Engl. J. Med.362, 875–885 (2010).
   PubMed Web of Science ®Google Scholar
• Sánchez-Aguilera A, Montalbán C, de la Cueva P et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin Lymphoma. Blood108(2), 662–668 (2006).
   PubMed Web of Science ®Google Scholar
• Devilard E, Bertucci F, Trempat P et al. Gene expression profiling defines molecular subtypes of classical Hodgkin´s disease. Oncogene21, 3095–3102 (2002).
   PubMed Web of Science ®Google Scholar
• Björkholm M, Holm G, Mellstedt H et al. Prognostic factors in Hodgkin’s disease. II. Role of the lymphocyte defect. Scand. J. Haematol.20(4), 306–318 (1978).
   PubMedGoogle Scholar
• Zielinski CC, Preis P, Aiginger P et al. Acute-β-proteins and parameters of humoral immunity in patients with advanced Hodgkin’s disease. J. Cancer Res. Clin. Oncol.110(1), 65–70 (1985).
   PubMed Web of Science ®Google Scholar
• Grimfors G, Andersson B, Tullgren O et al. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin’s disease. Br. J. Haematol.80(2), 166–171 (1992).
   PubMed Web of Science ®Google Scholar
• Enblad G, Sundström C, Gronowitz S et al. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin’s disease, with special reference to age and prognosis. Ann. Oncol.6(1), 65–70 (1995).
   PubMed Web of Science ®Google Scholar
• Gause A, Jung W, Schmits R, Tschiersch A et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin’s lymphoma. Ann. Oncol.3(Suppl. 4), 49–52 (1992).
   PubMed Web of Science ®Google Scholar
• Christiansen I, Enblad G, Kälkner KM et al. Soluble ICAM-1 in Hodgkin’s disease: a promising independent predictive marker for survival. Leuk. Lymphoma19(3–4), 243–251 (1995).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Cabanillas F, Lee JJ et al. Prognostic role of serum b 2-microglobulin in Hodgkin’s disease. J. Clin. Oncol.11(6), 1108–1011 (1993).
   PubMed Web of Science ®Google Scholar
• Eriksson B, Hagberg H, Glimelius B et al. Serum thymidine kinase as a prognostic marker in Hodgkin’s disease. Acta Radiol. Oncol.24(2), 167–171 (1985).
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Redman J, Cabanillas F et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res.53(9), 2118–2122 (1993).
   PubMed Web of Science ®Google Scholar
• Warzocha K, Bienvenu J, Ribeiro P et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients. Br. J. Cancer77(12), 2357–2362 (1998).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann. Oncol.13, 1356–1363 (2002).
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging31, 22–28 (2004).
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann. Oncol.16, 1514–1523 (2005).
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood106, 1376–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood112(10), 3989–3994 (2008).
   PubMed Web of Science ®Google Scholar
• Meignan M, Itti E, Gallamini A et al. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk. Lymphoma50(11), 1761–1764. (2009).
   PubMed Web of Science ®Google Scholar